We used the PK/PD model to estimate how the extendedcirculatinghalf-life of RABiT affects on-target drug binding in irradiated tumors.Since albumin circulates for days in mice and gradually accumulatesin tumor tissue, the model predicted that on-target prodrug activationincreases with greater delays between the time of RABiT injectionand the time of RT, plateauing after roughly 8 h once RT-generatedradicals become rate-limiting (Figure 4C). This evidence concerns the gene ALB and neoplasm.